sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
ÓÕ·¢ÐÍǰÏßÏÙ°©
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éúֳϵͳģ×Ó > ÓÕ·¢ÐÍǰÏßÏÙ°©

ǰÑÔ

ǰÏßÏÙ°©(prostate carcinomas)ÊÇÄÐÐÔÃÚÄòÉúֳϵͳ×î³£¼ûµÄÖ×Áö £¬¾ßÓв¡ÒòÖØ´ó¡¢·¢²¡²¿Î»Òþ²Ø¡¢Ç±ÔÚÆÚ³¤ÇÒ²¡ÀíÌåÏÖ¶àÑùµÈÌØµã¡£ÔÚÃÀ¹ú £¬Æä·¢²¡ÂÊÔÚÖ×Áö»¼ÕßÖÐÕ¼µÚ1λ £¬éæÃüÂÊÕ¼µÚ2λ¡£ÎÒ¹úÉÐÎÞǰÏßÏÙ°©·¢²¡ÂʺÍéæÃüÂʵÄ׼ȷͳ¼Æ×ÊÁÏ £¬ËäԶȱ·¦Î÷Å· £¬µ«Ëæ×ÅÎÒ¹úÉú³ÝÀÏÁ仯ºÍÒûʳ½á¹¹µÄ¸Ä±ä £¬Ç°ÏßÏÙ°©·¢²¡ÂÊÓÐÖðÄêÔö¸ßµÄÇ÷ÊÆ £¬ÇÒ³õÕïʱÒÑÓÐ30%~50£¥Ç°ÏßÏÙ°©»¼Õß±¬·¢×ªÒÆ¡£Òò´Ë £¬¶ÔǰÏßÏÙ°©µÄÑо¿¾ßÓкÜÊÇÖ÷ÒªµÄÒâÒå¡£¶¯ÎïÄ£×ÓÊǽøÒ»²½Ñо¿Ç°ÏßÏÙ°©µÄ·¢²¡»úÖÆ¡¢Ö×ÁöÓëËÞÖ÷µÄ¹ØÏµ¡¢Ö×ÁöÇÖÏ®Óë×ªÒÆÀú³ÌºÍÖÎÁƲ½·¥ÓÐÓÃÐÔµÄÖ÷Òª¹¤¾ß¡£ÏÖÔÚ £¬Æ¾Ö¤Ç°ÏßÏÙ°©¶¯ÎïÄ£×Ó½¨ÉèµÄÒªÁìÌØµã¿É·ÖΪ×Ô¾õºÍÓÕ·¢Ä£×Ó¡¢ÒÆÖ²ÐÔÄ£×Ó¡¢»ùÒòÐÞÊÎÄ£×ӵȡ£Ö÷Òª¶¯ÎïÖÖÀàÊÇ´óÊó¡¢Ð¡ÊóºÍÈ® £¬½üÄêÀ´ £¬ÒÅ´«¹¤³ÌСÊóÄ£×ÓÉú³¤ºÜ¿ì¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

»¯Ñ§Ö°©¼ÁDMAB»®·ÖÓ볤Ч±ûËáØºÍª(testosterone   propionate,TP)ÍŽáÓÕµ¼µÄǰÏßÏÙ°©Ä£×Ó·¢²¡ÂÊ½Ï¸ß £¬°©ÖׯðÔ´ÓÚ±³²àÒ¶¡¢ÖÐÒ¶ £¬ÓëÈËǰÏßÏÙ°©ÓÐͬԴÐÔ¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.6ÖÜÁäF344ÐÛÐÔ´óÊó,DMAB,TP¡£

2.´óÊó¸ôÖÜÆ¤ÏÂ×¢ÉäÒ»´ÎDMAB 50mg/kg £¬¹²20ÖÜ¡£Í¬Ê±Æ¤Ï°üÂñº¬ÓÐ40mg TPµÄ¹è½º¹Ü £¬¹²60ÖÜ £¬Ã¿6ÖÜ»»¹ÜÒ»´Î¡£

3.Ä£×Ó¼ì²â ¢ÙѪҺÖÐÐÛ¼¤ËØË®Æ½¼°ËáÐÔÁ×Ëáø»îÐÔ£ºÓÃÓÚÑо¿ØºÍª¶ÔǰÏßÏÙ°©±¬·¢µÄ×÷Óü°Ç°ÏßÏÙ°©µÄ¼ì²âÖ¸±ê£»¢ÚÒÅÌåÆÊ½â£º×Ðϸ¼ì²é¹Ç¡¢·Î¡¢¸ÎµÈ´¦ÓÐÎÞ×ªÒÆÔî £¬Ç°ÏßÏÙ¸÷Ò¶ÄÚÖ×Áö±¬·¢ÇéÐΣ»¢Û²¿·Ö´óÊó¿ÉÄܱ¬·¢¶ñÐÔÏËά×é֯ϸ°ûÁö £¬ÓÐʱ¿ÉÖ´óÊóéæÃü £¬ÆÊ½âÊ±Òª×¢ÖØÇ°ÏßÏÙ¸÷Ò¶ÄÚÖ×ÁöµÄ±¬·¢ÇéÐΣ»¢ÜʯÀ¯°üÂñ¡¢²¡ÀíÇÐÆ¬¼ì²é¸÷Ò¶ÄÚǰÏßÏÙ¼°ÆäËûÔàÆ÷¿ÉÒɲ¡Ôî¡£

¡¾Ä£×ÓÌØµã¡¿£º

°©ÖׯðÔ´ÓÚ±³²àÒ¶¡¢ÖÐÒ¶ £¬ÓëÈËǰÏßÏÙ°©ÓÐͬԴÐÔ £¬Ò²¾ßÓÐͨ¹ýѪµÀ¡¢Áܰ͵À×ªÒÆ¼°ÑªÇåËáÐÔÁ×ËáøÉý¸ßµÈÌØµã £¬ÇÒ²¡ÀíÀú³ÌÓë×éÖ¯·Ö½âÌØµãÓëÈËÏàËÆ £¬Òò¶ø±»ÒÔΪÊǽÏÁ¿ÀíÏëµÄÓÕ·¢ÐÔ¶¯ÎïÄ£×Ó¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

½«Ô­·¢µÄ´óÊó¼¤ËØÇ°ÏßÏÙ°©×é֯ݪֲµ½ÂãÊó±³²¿Æ¤Ï¡£½¨ÉèÁËݪֲÐÔǰÏßÏÙ°©¶¯ÎïÄ£×Ó¡£½¨ÉèµÄݪֲÖ×ÁöÉú³¤Ñ¸ËÙ¡¢¾ßÓнϸß×ªÒÆÄÜÁ¦ £¬ÓÈÆäÊÇÒ×±¬·¢·Î×ªÒÆ¡£¸ÃÖ×ÁöÖÆ×÷ʱ¼ä¶ÌÒ×ÓÚÊÓ²ì £¬¿ÉÓÃÓÚǰÏßÏÙ°©½þÈó¡¢×ªÒƺͼ¤ËØÒÀÀµÐÔµÄÑо¿¡£

 

²Î¿¼ÎÄÏ×£º

1.ÐìºèÐ÷ £¬ÍõÏþ²¨ £¬³ÂÁèÎä. ºÉÈËǰÏßÏÙ°©ÂãÊóÒÆÖ²ÁöÄ£×ӵĽ¨Éè¼°ÆäÓ¦ÓÃÑо¿£®ÊÊÓð©Ö¢ÔÓÖ¾ £¬2006,21(4):337-350

2.ÏôÔÆ±¸ £¬ÕÅÏþÍþ £¬Å£ÒÙ¶« £¬µÈ£®Ç°ÏßÏÙ°©¶¯ÎïÄ£×ÓʵÑ鶯Îï¿ÆÑ§ £¬2010, 27 (6):55-58

3.´ÞÁÖ £¬¹ØÖ¾³À£®ÝªÖ²ÐÔÐÛ¼¤ËØ·ÇÒÀÀµÐÍǰÏßÏÙ°©¶¯ÎïÄ£×ӵĽ¨Éè. ÖлªÃÚÄòÍâ¿ÆÔÓÖ¾ £¬2006,27(Suppl 2):39-41

4.¶­ÀÚ £¬ÕÅÏþÅô £¬Ò×ÉÜÇí £¬µÈ£®±í´ïÈËǰÏßÏÙ¸Éϸ°û¿¹Ô­Ð¡ÊóǰÏßÏÙ°©Ä£×ӵĽ¨ÉèÖйúʵÑ鶯Îïѧ±¨ £¬2009, 17(6):428-431

5.Gingrich JR, Barrios RJ, Morton RA, el al. Metastatic prostate cancer in a transgenic mouse. Cancer Res, 1996, 56 (18):4096-4102

6.Ittmann M, Huang J, Radaelli E, el al. Animal models of human prostate cancer:the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee, Cancer Res, 2013, 73 (9):2718-2736

7.Jones LW,Antonelli J,Masko EM,et al. Exercise modulation of the host-tumor interaction in an ortholop1c model of murine prostate cancer. J Appl Physiol (1985), 2012, 113 (2):263-272

8.Klyushnenkova EN, Kouiavskaia DV,Parkins CJ, et al. A cytomegalovirus-based vaccine expressing a single tumor­ specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J lmmunother,2012,35 (5):390-399

9.Shen L, Ciesielski M, Ramakrishnan  S, el al.Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One, 2012, 7 (1): e30815

10.Shibata MA,Jorcyk CL.Liu ML,et al. The C3(1)/ SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol Pathol, 1998, 26 (1): 177-182

11.Shirai T,Imaida K,Iwasaki S,et al. Sequential observation of rat prostate lesion development induced by 3, 2'-dimelhyl-4-aminobiphenyl and testosterone. Jpn J Cance.r Res, 1993, 84 (1):20-25

12.Shirai T, Takahashi S, Cui L, et al. Experimental prostate carcinogenesis-rodent models. Mutat Res, 2000, 462 (2-3):219-226

13.Wang X, An Z, Geller J,et al. High-malignancy orthotopic nude mouse model of human prostate cancer LNCaP.Prostate, 1999,39(3): 182-186

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éúֳϵͳģ×Ó > ÓÕ·¢ÐÍǰÏßÏÙ°©
ÓÕ·¢ÐÍǰÏßÏÙ°©

ǰÑÔ

ǰÏßÏÙ°©(prostate carcinomas)ÊÇÄÐÐÔÃÚÄòÉúֳϵͳ×î³£¼ûµÄÖ×Áö £¬¾ßÓв¡ÒòÖØ´ó¡¢·¢²¡²¿Î»Òþ²Ø¡¢Ç±ÔÚÆÚ³¤ÇÒ²¡ÀíÌåÏÖ¶àÑùµÈÌØµã¡£ÔÚÃÀ¹ú £¬Æä·¢²¡ÂÊÔÚÖ×Áö»¼ÕßÖÐÕ¼µÚ1λ £¬éæÃüÂÊÕ¼µÚ2λ¡£ÎÒ¹úÉÐÎÞǰÏßÏÙ°©·¢²¡ÂʺÍéæÃüÂʵÄ׼ȷͳ¼Æ×ÊÁÏ £¬ËäԶȱ·¦Î÷Å· £¬µ«Ëæ×ÅÎÒ¹úÉú³ÝÀÏÁ仯ºÍÒûʳ½á¹¹µÄ¸Ä±ä £¬Ç°ÏßÏÙ°©·¢²¡ÂÊÓÐÖðÄêÔö¸ßµÄÇ÷ÊÆ £¬ÇÒ³õÕïʱÒÑÓÐ30%~50£¥Ç°ÏßÏÙ°©»¼Õß±¬·¢×ªÒÆ¡£Òò´Ë £¬¶ÔǰÏßÏÙ°©µÄÑо¿¾ßÓкÜÊÇÖ÷ÒªµÄÒâÒå¡£¶¯ÎïÄ£×ÓÊǽøÒ»²½Ñо¿Ç°ÏßÏÙ°©µÄ·¢²¡»úÖÆ¡¢Ö×ÁöÓëËÞÖ÷µÄ¹ØÏµ¡¢Ö×ÁöÇÖÏ®Óë×ªÒÆÀú³ÌºÍÖÎÁƲ½·¥ÓÐÓÃÐÔµÄÖ÷Òª¹¤¾ß¡£ÏÖÔÚ £¬Æ¾Ö¤Ç°ÏßÏÙ°©¶¯ÎïÄ£×Ó½¨ÉèµÄÒªÁìÌØµã¿É·ÖΪ×Ô¾õºÍÓÕ·¢Ä£×Ó¡¢ÒÆÖ²ÐÔÄ£×Ó¡¢»ùÒòÐÞÊÎÄ£×ӵȡ£Ö÷Òª¶¯ÎïÖÖÀàÊÇ´óÊó¡¢Ð¡ÊóºÍÈ® £¬½üÄêÀ´ £¬ÒÅ´«¹¤³ÌСÊóÄ£×ÓÉú³¤ºÜ¿ì¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

»¯Ñ§Ö°©¼ÁDMAB»®·ÖÓ볤Ч±ûËáØºÍª(testosterone   propionate,TP)ÍŽáÓÕµ¼µÄǰÏßÏÙ°©Ä£×Ó·¢²¡ÂÊ½Ï¸ß £¬°©ÖׯðÔ´ÓÚ±³²àÒ¶¡¢ÖÐÒ¶ £¬ÓëÈËǰÏßÏÙ°©ÓÐͬԴÐÔ¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.6ÖÜÁäF344ÐÛÐÔ´óÊó,DMAB,TP¡£

2.´óÊó¸ôÖÜÆ¤ÏÂ×¢ÉäÒ»´ÎDMAB 50mg/kg £¬¹²20ÖÜ¡£Í¬Ê±Æ¤Ï°üÂñº¬ÓÐ40mg TPµÄ¹è½º¹Ü £¬¹²60ÖÜ £¬Ã¿6ÖÜ»»¹ÜÒ»´Î¡£

3.Ä£×Ó¼ì²â ¢ÙѪҺÖÐÐÛ¼¤ËØË®Æ½¼°ËáÐÔÁ×Ëáø»îÐÔ£ºÓÃÓÚÑо¿ØºÍª¶ÔǰÏßÏÙ°©±¬·¢µÄ×÷Óü°Ç°ÏßÏÙ°©µÄ¼ì²âÖ¸±ê£»¢ÚÒÅÌåÆÊ½â£º×Ðϸ¼ì²é¹Ç¡¢·Î¡¢¸ÎµÈ´¦ÓÐÎÞ×ªÒÆÔî £¬Ç°ÏßÏÙ¸÷Ò¶ÄÚÖ×Áö±¬·¢ÇéÐΣ»¢Û²¿·Ö´óÊó¿ÉÄܱ¬·¢¶ñÐÔÏËά×é֯ϸ°ûÁö £¬ÓÐʱ¿ÉÖ´óÊóéæÃü £¬ÆÊ½âÊ±Òª×¢ÖØÇ°ÏßÏÙ¸÷Ò¶ÄÚÖ×ÁöµÄ±¬·¢ÇéÐΣ»¢ÜʯÀ¯°üÂñ¡¢²¡ÀíÇÐÆ¬¼ì²é¸÷Ò¶ÄÚǰÏßÏÙ¼°ÆäËûÔàÆ÷¿ÉÒɲ¡Ôî¡£

¡¾Ä£×ÓÌØµã¡¿£º

°©ÖׯðÔ´ÓÚ±³²àÒ¶¡¢ÖÐÒ¶ £¬ÓëÈËǰÏßÏÙ°©ÓÐͬԴÐÔ £¬Ò²¾ßÓÐͨ¹ýѪµÀ¡¢Áܰ͵À×ªÒÆ¼°ÑªÇåËáÐÔÁ×ËáøÉý¸ßµÈÌØµã £¬ÇÒ²¡ÀíÀú³ÌÓë×éÖ¯·Ö½âÌØµãÓëÈËÏàËÆ £¬Òò¶ø±»ÒÔΪÊǽÏÁ¿ÀíÏëµÄÓÕ·¢ÐÔ¶¯ÎïÄ£×Ó¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

½«Ô­·¢µÄ´óÊó¼¤ËØÇ°ÏßÏÙ°©×é֯ݪֲµ½ÂãÊó±³²¿Æ¤Ï¡£½¨ÉèÁËݪֲÐÔǰÏßÏÙ°©¶¯ÎïÄ£×Ó¡£½¨ÉèµÄݪֲÖ×ÁöÉú³¤Ñ¸ËÙ¡¢¾ßÓнϸß×ªÒÆÄÜÁ¦ £¬ÓÈÆäÊÇÒ×±¬·¢·Î×ªÒÆ¡£¸ÃÖ×ÁöÖÆ×÷ʱ¼ä¶ÌÒ×ÓÚÊÓ²ì £¬¿ÉÓÃÓÚǰÏßÏÙ°©½þÈó¡¢×ªÒƺͼ¤ËØÒÀÀµÐÔµÄÑо¿¡£

 

²Î¿¼ÎÄÏ×£º

1.ÐìºèÐ÷ £¬ÍõÏþ²¨ £¬³ÂÁèÎä. ºÉÈËǰÏßÏÙ°©ÂãÊóÒÆÖ²ÁöÄ£×ӵĽ¨Éè¼°ÆäÓ¦ÓÃÑо¿£®ÊÊÓð©Ö¢ÔÓÖ¾ £¬2006,21(4):337-350

2.ÏôÔÆ±¸ £¬ÕÅÏþÍþ £¬Å£ÒÙ¶« £¬µÈ£®Ç°ÏßÏÙ°©¶¯ÎïÄ£×ÓʵÑ鶯Îï¿ÆÑ§ £¬2010, 27 (6):55-58

3.´ÞÁÖ £¬¹ØÖ¾³À£®ÝªÖ²ÐÔÐÛ¼¤ËØ·ÇÒÀÀµÐÍǰÏßÏÙ°©¶¯ÎïÄ£×ӵĽ¨Éè. ÖлªÃÚÄòÍâ¿ÆÔÓÖ¾ £¬2006,27(Suppl 2):39-41

4.¶­ÀÚ £¬ÕÅÏþÅô £¬Ò×ÉÜÇí £¬µÈ£®±í´ïÈËǰÏßÏÙ¸Éϸ°û¿¹Ô­Ð¡ÊóǰÏßÏÙ°©Ä£×ӵĽ¨ÉèÖйúʵÑ鶯Îïѧ±¨ £¬2009, 17(6):428-431

5.Gingrich JR, Barrios RJ, Morton RA, el al. Metastatic prostate cancer in a transgenic mouse. Cancer Res, 1996, 56 (18):4096-4102

6.Ittmann M, Huang J, Radaelli E, el al. Animal models of human prostate cancer:the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee, Cancer Res, 2013, 73 (9):2718-2736

7.Jones LW,Antonelli J,Masko EM,et al. Exercise modulation of the host-tumor interaction in an ortholop1c model of murine prostate cancer. J Appl Physiol (1985), 2012, 113 (2):263-272

8.Klyushnenkova EN, Kouiavskaia DV,Parkins CJ, et al. A cytomegalovirus-based vaccine expressing a single tumor­ specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J lmmunother,2012,35 (5):390-399

9.Shen L, Ciesielski M, Ramakrishnan  S, el al.Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One, 2012, 7 (1): e30815

10.Shibata MA,Jorcyk CL.Liu ML,et al. The C3(1)/ SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol Pathol, 1998, 26 (1): 177-182

11.Shirai T,Imaida K,Iwasaki S,et al. Sequential observation of rat prostate lesion development induced by 3, 2'-dimelhyl-4-aminobiphenyl and testosterone. Jpn J Cance.r Res, 1993, 84 (1):20-25

12.Shirai T, Takahashi S, Cui L, et al. Experimental prostate carcinogenesis-rodent models. Mutat Res, 2000, 462 (2-3):219-226

13.Wang X, An Z, Geller J,et al. High-malignancy orthotopic nude mouse model of human prostate cancer LNCaP.Prostate, 1999,39(3): 182-186

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿